Foghorn Therapeutics Inc.

NASDAQ:FHTX

4.65 (USD) • At close January 8, 2025
Bedrijfsnaam Foghorn Therapeutics Inc.
Symbool FHTX
Munteenheid USD
Prijs 4.65
Beurswaarde 258,507,915
Dividendpercentage 0%
52-weken bereik 2.7 - 10.25
Industrie Biotechnology
Sector Healthcare
CEO Mr. Adrian H. B. Gottschalk
Website https://foghorntx.com

An error occurred while fetching data.

Over Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic

Vergelijkbare Aandelen

Castle Biosciences, Inc. logo

Castle Biosciences, Inc.

CSTL

32.72 USD

Sangamo Therapeutics, Inc. logo

Sangamo Therapeutics, Inc.

SGMO

1.215 USD

The Pennant Group, Inc. logo

The Pennant Group, Inc.

PNTG

26.57 USD

Bioventus Inc. logo

Bioventus Inc.

BVS

9.58 USD

Surmodics, Inc. logo

Surmodics, Inc.

SRDX

39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)